# Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

> **NCT00045786** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 18 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** CC-1088

## Key facts

- **NCT ID:** NCT00045786
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2001-12
- **Final completion:** 2003-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045786, "Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00045786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*